Skip to main content
Premium Trial:

Request an Annual Quote

After Gene Logic, Markowitz Is Pinned by JGI as CIO

Premium

It seems that wherever Victor Markowitz decides to go, the CIO title is sure to follow.

Joining Gene Logic in 1997 after 10 years at Lawrence Berkeley National Lab, the Israeli-born computer scientist led the development of the company’s Genesis data management software, and soon rose to CIO. In recent months, as Gene Logic’s business strategy evolved toward providing clinical trials services, he returned to Lawrence Berkeley to lead an academic group. Now, he finds himself with an additional position at the DOE’s Joint Genome Institute. Guess what: he’s CIO.

There’s a reason JGI is giving Markowitz a corporate title. When he rejoined the national lab in February, Markowitz created the Biological Data Management and Technology Center, with a mission to apply industry practices for designing and supporting data management software in an academic environment. With its sequencers churning out more and more genomic data, JGI was a natural first client. Sure enough, JGI Director Eddy Rubin solicited advice from Markowitz’s group on how to better handle that data, and then, says Markowitz, he asked him to implement those recommendations as CIO.

Typically, an academic group’s approach to software development is more “attuned to rapid prototyping of systems” than establishing an organized approach, Markowitz says. As the scale and complexity of data management within that group grows, he adds, it’s useful to apply practices common to industry, such as introducing traditional life cycles of software and system development, and creating an infrastructure for software support. “There is nothing deep or revolutionary about it.” he says. “It’s basically taking principles that have been used in industry for many years, and applying them in this setting.”

In fact, as JGI continues to expand its capacity for sequencing the genomes of microbes and other organisms, solving its data management needs demands nothing less than an industrial-scale approach. “More and more it’s looking like a company — without the profit — and you need the basic organization to deal with it,” Markowitz says. “The problem is of scale and growth.”

— John S. MacNeil

 

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.